Condition: Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) · Sponsor: Changzhou Qianhong Bio-pharma Co., Ltd.
The purpose of this study is to assess the safety and efficacy of QHRD107 capsule combined with Venclexta and azacitidine in the treatment of relapsed/refractory acute myeloid leukemia: a single-arm, open, multicenter Phase IIa study
This description comes directly from the study's public registry record.
Li Junmin, Doctor · 13817712211 · lijunmin@medmail.com.cn
Always discuss trial participation with your own doctor first.
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Zhongnan Hospital of Wuhan University | Wuhan, Hubei, China | Recruiting |
| The First People's Hospital of Changzhou | Changzhou, Jiangsu, China | Recruiting |
| Huai 'an First People's Hospital | Huaian, Jiangsu, China | Recruiting |
| Zhongda Hospital | Nanjing, Jiangsu, China | Recruiting |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
| ShengJing Hospital | Shenyang, Liaoning, China | Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shangdong, China | Recruiting |
| Tongren Hospital Shanghai Jiao Tong University School Of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| Ruijin hospitol | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06532058